Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA bonuses rise

Executive Summary

FDA bonuses exceeding $4,000 increased by an estimated $8 million in 2007 over 2006 figures, according to data released by the House Energy and Commerce Committee. The agency's highest-paid officials received many of the retention bonuses, which totaled $35 million last year. "These back-scratching bonuses could be used to hire inspectors that might have gone to China and uncovered the unsafe manufacturing practices that led to the heparin deaths," said Committee Chair John Dingell, D-Mich. Such outcries, which also followed the announcement of FDA bonus figures last year, are drawing more scrutiny as the agency calls for additional funds to keep pace with scientific advancements (1"The Pink Sheet," July 23, 2007, In Brief)

FDA bonuses exceeding $4,000 increased by an estimated $8 million in 2007 over 2006 figures, according to data released by the House Energy and Commerce Committee. The agency's highest-paid officials received many of the retention bonuses, which totaled $35 million last year. "These back-scratching bonuses could be used to hire inspectors that might have gone to China and uncovered the unsafe manufacturing practices that led to the heparin deaths," said Committee Chair John Dingell, D-Mich. Such outcries, which also followed the announcement of FDA bonus figures last year, are drawing more scrutiny as the agency calls for additional funds to keep pace with scientific advancements (1 'The Pink Sheet,' July 23, 2007, In Brief).

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel